Genetic brain white matter disorders, also called leukodystrophies, lead
to considerable clinical handicap, ranging from mild to severe.
Patients are most often children and die early in life. As yet, the
majority of leukodystrophies lack an effective treatment. While all
leukodystrophies share major pathological traits (i.e. white matter
disruption), our understanding of the cascade of events leading from the
genetic defect to this detrimental outcome is still poor. Recent
evidences suggest that besides white matter and myelin, also the nerve
cells (neurons, also called grey matter) and their processes (axons) are
damaged from early disease stages on. In our project, we want to
explore this grey matter involvement in different types of
leukodystrophies with an innovative approach. We will combine modern
–OMICS and high-resolution imaging with advanced 2D and 3D induced
pluripotent stem cell (iPSC)-based cellular models. We want to study
patient grey and white matter cells using different model systems, from
reductive in vitro cultures up to complex in vivo microenvironments, to
know how they influence each other, and whether different patients
present with common defects. In the future, this might be a good
approach to study for drug screening for leukodystrophies. To reach this
goal, the project will combine the expertise of (i) recognized European
research teams working in the field of white matter diseases and (ii)
leukodystrophy patients and families associations devoted to
leukodystrophies.